To explore this hypothesis further, we tested a small molecule BET inhibitor, I-BET151, in a STAM mouse model22 at two distinct time windows to evaluate its efficacy on early NASH (“NASH study”, week 6–9) and during fibrosis onset (“fibrosis study”, week 9–12) (Fig. 1). This evidence concerns the gene DNER and metabolic dysfunction-associated steatohepatitis.